CY2019018I1 - Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων - Google Patents

Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων

Info

Publication number
CY2019018I1
CY2019018I1 CY2019018C CY2019018C CY2019018I1 CY 2019018 I1 CY2019018 I1 CY 2019018I1 CY 2019018 C CY2019018 C CY 2019018C CY 2019018 C CY2019018 C CY 2019018C CY 2019018 I1 CY2019018 I1 CY 2019018I1
Authority
CY
Cyprus
Prior art keywords
necrosion
antibody molecules
human tumor
factor alpha
molecules specific
Prior art date
Application number
CY2019018C
Other languages
English (en)
Other versions
CY2019018I2 (el
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2019018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of CY2019018I1 publication Critical patent/CY2019018I1/el
Publication of CY2019018I2 publication Critical patent/CY2019018I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
CY2019018C 2000-06-06 2019-04-19 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων CY2019018I2 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
EP09176251A EP2230308B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
EP01934209A EP1287140B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
EP10010795.2A EP2308975B1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
CY2019018I1 true CY2019018I1 (el) 2020-05-29
CY2019018I2 CY2019018I2 (el) 2020-05-29

Family

ID=9893121

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20101100219T CY1109889T1 (el) 2000-06-06 2010-03-09 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
CY2010011C CY2010011I1 (el) 2000-06-06 2010-05-13 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
CY20131100333T CY1114143T1 (el) 2000-06-06 2013-04-23 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY20161101159T CY1118220T1 (el) 2000-06-06 2016-11-10 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY20191100095T CY1121173T1 (el) 2000-06-06 2019-01-24 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY2019018C CY2019018I2 (el) 2000-06-06 2019-04-19 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CY20101100219T CY1109889T1 (el) 2000-06-06 2010-03-09 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
CY2010011C CY2010011I1 (el) 2000-06-06 2010-05-13 Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
CY20131100333T CY1114143T1 (el) 2000-06-06 2013-04-23 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY20161101159T CY1118220T1 (el) 2000-06-06 2016-11-10 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY20191100095T CY1121173T1 (el) 2000-06-06 2019-01-24 Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων

Country Status (43)

Country Link
US (4) US7012135B2 (el)
EP (4) EP3059314B1 (el)
JP (3) JP4064812B2 (el)
KR (1) KR20020047097A (el)
CN (1) CN1289671C (el)
AP (1) AP2092A (el)
AR (1) AR033978A1 (el)
AT (1) ATE451460T1 (el)
AU (1) AU783756B2 (el)
BE (1) BE2010C019I2 (el)
BG (1) BG66072B1 (el)
BR (2) BRPI0106682B8 (el)
CA (2) CA2707766C (el)
CY (6) CY1109889T1 (el)
CZ (1) CZ300737B6 (el)
DE (3) DE122010000027I1 (el)
DK (4) DK2230308T3 (el)
EC (1) ECSP024210A (el)
ES (5) ES2600080T3 (el)
FR (1) FR10C0015I2 (el)
GB (2) GB0013810D0 (el)
HK (2) HK1051385A1 (el)
HU (4) HU230553B1 (el)
IL (3) IL147992A0 (el)
IS (2) IS2808B (el)
LT (1) LT2308975T (el)
LU (1) LU91674I2 (el)
MX (1) MXPA01013440A (el)
MY (1) MY136603A (el)
NL (1) NL300982I9 (el)
NO (4) NO334808B1 (el)
NZ (1) NZ516596A (el)
OA (1) OA12282A (el)
PE (1) PE20020292A1 (el)
PL (2) PL218516B1 (el)
PT (4) PT3059314T (el)
RU (1) RU2303604C2 (el)
SI (3) SI2308975T1 (el)
SK (1) SK288343B6 (el)
TR (1) TR201900227T4 (el)
TW (2) TWI316088B (el)
WO (1) WO2001094585A1 (el)
ZA (1) ZA200200097B (el)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2003080674A1 (en) * 2002-03-20 2003-10-02 Pharmacia Corporation Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
BR122019027974B1 (pt) 2002-05-02 2022-06-14 Wyeth Holdings Corporation Composição compreendendo conjugado monomérico de derivado de caliqueamicina/anticorpo anti-cd22 e seu uso
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
TWI430810B (zh) * 2002-07-19 2014-03-21 Abbott Lab S A ＴＮＦα相關病症之治療
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1597299A2 (en) * 2003-02-19 2005-11-23 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
ATE414106T1 (de) * 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
WO2005017162A2 (en) * 2003-08-13 2005-02-24 Sandoz Ag Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
US20060173167A1 (en) * 2003-08-13 2006-08-03 Gunter Stempfer Process for the purification of recombinant polypeptides
GB0319601D0 (en) * 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
BRPI0611765B1 (pt) 2005-06-07 2022-09-27 Esbatech Ag Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
CA2648582C (en) 2006-04-07 2016-12-06 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
CA2656347A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2008223091B2 (en) * 2007-03-02 2014-04-24 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
US20080305115A1 (en) * 2007-06-07 2008-12-11 Tice Thomas R Reduced-mass, long-acting dosage forms
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
BRPI0907485A2 (pt) * 2008-02-05 2015-08-04 Delenex Therapeutics Ag Polipeptídeos de ligação a antígeno contra degeneração de cartilagem
RU2532832C2 (ru) * 2008-05-07 2014-11-10 Аргос Терапьютикс, Инк. Гуманизированные антитела против альфа-интерферона человека
AU2009264565C1 (en) 2008-06-25 2022-01-27 Novartis Ag Stable and soluble antibodies inhibiting VEGF
PT3444274T (pt) * 2008-06-25 2021-03-17 Novartis Ag Anticorpos que inibem tnf estáveis e solúveis
CA2728004C (en) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
ES2677003T3 (es) 2008-06-25 2018-07-27 Esbatech, An Alcon Biomedical Research Unit Llc Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
PE20120586A1 (es) * 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
HUE040306T2 (hu) 2009-09-24 2019-03-28 Ucb Biopharma Sprl Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént
EA030827B1 (ru) 2009-10-23 2018-10-31 Милленниум Фармасьютикалз, Инк. Анти-gcc антитело и его применения
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
CA2791866A1 (en) 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
SG184473A1 (en) 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
WO2012164083A1 (en) 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
HUE035674T2 (en) 2011-07-13 2018-05-28 Ucb Biopharma Sprl Bacterial host strains expressing recombinant DSBC
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
RU2653757C2 (ru) 2011-09-23 2018-05-14 Интрексон Актобиотикс Н.В. Модифицированные грамположительные бактерии и их применение
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
EP2882776B1 (en) 2012-08-13 2018-05-02 F.Hoffmann-La Roche Ag Anti-jagged anitbodies and methods of use
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
MY184085A (en) 2014-12-22 2021-03-17 Ucb Biopharma Sprl Method of protein manufacture
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017122180A1 (en) 2016-01-14 2017-07-20 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CA3025377A1 (en) 2016-06-02 2017-12-07 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
RU2020117698A (ru) 2017-12-01 2022-01-04 Эббви Инк. Агонист глюкокортикоидного рецептора и его иммуноконъюгаты
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
KR20230146032A (ko) 2021-02-15 2023-10-18 다케다 야쿠힌 고교 가부시키가이샤 Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
CN117500816A (zh) 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023046930A1 (en) 2021-09-24 2023-03-30 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ATE399809T1 (de) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
EP1287140A1 (en) 2003-03-05
KR20020047097A (ko) 2002-06-21
PL353960A1 (en) 2003-12-15
HK1051385A1 (en) 2003-08-01
TR201900227T4 (tr) 2019-02-21
HK1148776A1 (en) 2011-09-16
AP2092A (en) 2010-02-28
BG106278A (bg) 2002-12-29
NL300982I9 (nl) 2019-05-06
ES2230975A1 (es) 2005-05-01
DE60140738D1 (de) 2010-01-21
BRPI0106682B8 (pt) 2021-05-25
NZ516596A (en) 2004-07-30
IS2808B (is) 2012-09-15
DE122010000027I1 (de) 2010-08-12
PE20020292A1 (es) 2002-05-08
LT2308975T (lt) 2016-11-10
JP2007105043A (ja) 2007-04-26
WO2001094585A1 (en) 2001-12-13
HUP1600016A2 (en) 2002-10-28
DK1287140T3 (da) 2010-04-19
US7977464B2 (en) 2011-07-12
SI2230308T1 (sl) 2013-06-28
HU230553B1 (hu) 2016-11-28
EP1287140B1 (en) 2009-12-09
ES2403217T3 (es) 2013-05-16
HU230561B1 (hu) 2016-12-28
HUP0202346A3 (en) 2004-11-29
RU2303604C2 (ru) 2007-07-27
NO2014026I2 (no) 2018-02-14
GB2366800A (en) 2002-03-20
CY1114143T1 (el) 2016-07-27
US20060233800A1 (en) 2006-10-19
MXPA01013440A (es) 2003-09-04
AU783756B2 (en) 2005-12-01
AR033978A1 (es) 2004-01-21
CN1383450A (zh) 2002-12-04
DK2308975T3 (da) 2016-10-31
PL218516B1 (pl) 2014-12-31
FR10C0015I2 (fr) 2011-12-30
PT2230308E (pt) 2013-05-03
EP2308975B1 (en) 2016-08-10
NO341218B1 (no) 2017-09-11
CZ300737B6 (cs) 2009-07-29
US20020151682A1 (en) 2002-10-17
SI2308975T1 (sl) 2016-11-30
BG66072B1 (bg) 2011-01-31
NO20160694A1 (no) 2002-04-08
DK2230308T3 (da) 2013-05-06
IL195085A0 (en) 2009-08-03
NO334808B1 (no) 2014-06-02
EP3059314A1 (en) 2016-08-24
ES2337763T3 (es) 2010-04-29
US7186820B2 (en) 2007-03-06
NO20020554L (no) 2002-04-08
IS3016B (is) 2019-10-15
SK3152002A3 (en) 2002-07-02
CA2380298A1 (en) 2001-12-13
CN1289671C (zh) 2006-12-13
US7402662B2 (en) 2008-07-22
US20030026805A1 (en) 2003-02-06
HUS1700013I1 (hu) 2017-08-28
CA2707766C (en) 2013-05-21
ECSP024210A (es) 2002-05-23
DE10192353T1 (de) 2003-05-22
CY1109889T1 (el) 2012-01-25
OA12282A (en) 2006-05-11
CA2380298C (en) 2010-09-28
PT3059314T (pt) 2019-02-01
EP2230308B1 (en) 2013-01-23
BE2010C019I2 (el) 2020-08-20
NO20020554D0 (no) 2002-02-04
DK3059314T3 (en) 2019-02-18
IS6217A (is) 2002-01-03
NO2014026I1 (no) 2014-10-23
HU230669B1 (hu) 2017-07-28
LU91674I2 (fr) 2010-05-31
TW200817430A (en) 2008-04-16
JP2009171966A (ja) 2009-08-06
EP2308975A1 (en) 2011-04-13
FR10C0015I1 (el) 2010-04-16
JP4476989B2 (ja) 2010-06-09
ATE451460T1 (de) 2009-12-15
IL147992A0 (en) 2002-09-12
AP2002002690A0 (en) 2002-12-31
NL300982I1 (el) 2019-05-01
CZ2002837A3 (cs) 2002-05-15
HUP0202346A2 (en) 2002-10-28
LU91674I9 (el) 2019-01-03
PT2308975T (pt) 2016-11-14
PL399351A1 (pl) 2012-12-17
CY2019018I2 (el) 2020-05-29
NO339282B1 (no) 2016-11-21
CY2010011I2 (el) 2012-01-25
NO20131316L (no) 2002-04-08
CA2707766A1 (en) 2001-12-13
EP2230308A1 (en) 2010-09-22
IL147992A (en) 2009-06-15
GB2366800B (en) 2005-01-19
JP4064812B2 (ja) 2008-03-19
US7012135B2 (en) 2006-03-14
US20080269465A1 (en) 2008-10-30
JP5185143B2 (ja) 2013-04-17
EP3059314B1 (en) 2018-10-24
ZA200200097B (en) 2003-01-06
HUP1600483A2 (el) 2002-10-28
SI1287140T1 (sl) 2010-04-30
PT1287140E (pt) 2010-03-08
CY1118220T1 (el) 2017-06-28
SK288343B6 (sk) 2016-04-01
JP2003535591A (ja) 2003-12-02
GB0013810D0 (en) 2000-07-26
BRPI0106682B1 (pt) 2020-10-13
ES2230975B2 (es) 2007-04-16
ES2707714T3 (es) 2019-04-04
BR0106682A (pt) 2002-05-14
TWI353358B (en) 2011-12-01
ES2600080T3 (es) 2017-02-07
CY1121173T1 (el) 2020-05-29
CY2010011I1 (el) 2012-01-25
MY136603A (en) 2008-10-31
GB0128386D0 (en) 2002-01-16
TWI316088B (en) 2009-10-21
PL212738B1 (pl) 2012-11-30
AU6051101A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
CY2019018I2 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
CY2015018I2 (el) Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
SE0202258D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XVIII
SE0202261D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XXI
SE0202254D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XIV
SE0202260D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XX
SE0201867D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy I
SE0201953D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy II
SE0201955D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy V
SE0202251D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XI
SE0202255D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XV
SE0201960D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy X
SE0201954D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy III
SE0202256D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy XVI
SE0201956D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy VI
SE0001569D0 (sv) New compounds and their use in the treatment of alopecia